Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen composition for preventing and treating pig secondary infected respiratory diseases and its preparation method and application

A technology for respiratory diseases and secondary infection, applied in the field of veterinary vaccines, can solve the problems of decreased efficacy of live vaccines, high stress in pigs, and high viscosity of oily adjuvants, etc.

Active Publication Date: 2017-06-30
PU LIKE BIO ENG
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no combination vaccine of Haemophilus parasuis and PRRS in the market, or the combined use of the two at the same time. This is because the existence of inactivated Haemophilus parasuis vaccine will affect the immune effect of PRRS live vaccine. The possible reasons are as follows: first, the oily adjuvant used in the inactivated vaccine is too viscous to be used as a diluent to dilute the live vaccine; second, the toxic components contained in the inactivated vaccine: inactivating agents such as formaldehyde; preservatives such as thimerosal, Nitrogen and sodium; toxins such as a large amount of endotoxin, metabolites and miscellaneous proteins in the culture process have a significant impact on the toxicity of live vaccines and reduce the efficacy of live vaccines
Moreover, commercially available commercial vaccines need to be immunized multiple times, the cost is high, and the stress on pigs is relatively large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen composition for preventing and treating pig secondary infected respiratory diseases and its preparation method and application
  • Antigen composition for preventing and treating pig secondary infected respiratory diseases and its preparation method and application
  • Antigen composition for preventing and treating pig secondary infected respiratory diseases and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] The present invention will be further described below in conjunction with specific embodiments, and the advantages and characteristics of the present invention will become clearer along with the description. However, these embodiments are only exemplary and do not constitute any limitation to the scope of the present invention. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention. Example 1 Tidal microcarrier suspension Large-scale Production of Porcine Reproductive and Respiratory Syndrome Virus and Preparation of Vaccine in Buoyant Bioreactor

[0070] The microcarrier used in the present embodiment is polyester fiber, and the virus strain that is used to prepare reproductive and respiratory syndrome ...

Embodiment 2

[0085] The screening of embodiment 2 adjuvants

[0086] Using Haemophilus parasuis serum type 4 JS strain, type 5 ZJ strain antigen, respectively with white oil adjuvant, 206 adjuvant, nano aluminum hydroxide gel adjuvant, Montanide IMS1313 VG, MontanideISA15A VG, Montanide GEL 01 PR and Montanide GEL ST polymer adjuvant was formulated separately, and the antigen content of the finished vaccine was 2.0×10 for the serum type 4 JS strain and type 5 ZJ strain before inactivation. 9 CFU / head serving. The prepared vaccine was tested for compatibility with the PRRS vaccine prepared in Example 1 after the character test, the safety test and the potency test.

[0087] (1) Trait test (see Table 2)

[0088] Table 2 Appearance, sterility test and viscosity determination of vaccines with various adjuvants

[0089]

[0090] (2) Safety: The prepared vaccine was injected intramuscularly into 5 healthy susceptible pigs, 4mL each. Within 14 days, some vaccine groups had local or system...

Embodiment 3

[0104] Embodiment 3 Haemophilus parasuis inactivated vaccine (JS strain+ZJ strain) preparation

[0105] Haemophilus parasuis inactivated vaccine (JS strain + ZJ strain), which has been inactivated, ultra-filtered and passed the security inspection, uses Haemophilus parasuis serum type 4 JS strain, type 5 ZJ strain antigen, and MontanideGEL 01 ST The adjuvant is mixed and prepared, wherein the ratio of the above two antigens is 1:1, accounting for 90% of the total volume of the vaccine, the content of the adjuvant is 10%, and the antigen content of the finished vaccine is 4 JS strains and 5 ZJ strains before inactivation. The number of live bacteria was 2.1×10 9 CFU / head serving.

[0106] 1. Strains

[0107] 1.1 The JS strain of Haemophilus parasuis serotype 4 was isolated and identified by Pulaike Bioengineering Co., Ltd., and has been preserved in the China Center for Type Culture Collection. The preservation date is May 18, 2011, and the preservation number is: CCTCC M2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an antigenic composition for preventing and treating respiratory diseases of secondary infection in pigs, wherein the antigenic composition comprises at least one immunizing amount of porcine reproductive and respiratory syndrome antigen and at least one immunizing amount of parapig Haemophilus antigen and adjuvant, the porcine reproductive and respiratory syndrome antigen and Haemophilus parasuis antigen each independently include attenuated live whole antigen, inactivated whole antigen, subunit antigen, recombinant live vector antigen and DNA vector The antigen; the antigen composition will not produce mutual immune interference or influence of the two antigen components, and the porcine reproductive and respiratory syndrome and Haemophilus parasuis antigens have the effect of mutually enhancing the immune effect, and the antigen composition inoculation The procedure is simple and safe.

Description

technical field [0001] The invention relates to a vaccine composition for preventing and treating Haemophilus parasuis and porcine reproductive and respiratory syndrome and a preparation method thereof, belonging to the field of veterinary vaccines. Background technique [0002] Porcine reproductive and respiratory syndrome (Porcine Reproductive and Respiratory Syndrome, PRRS), also known as porcine blue ear disease, is caused by single-stranded positive-sense RNA porcine reproductive and respiratory syndrome virus, and is characterized by reproductive disorders (abortion, stillbirth) in pregnant sows. , mummified fetuses) and pigs of various ages, especially piglets, are characterized by respiratory diseases, and have now become one of the main diseases in large-scale pig farms. The highly pathogenic porcine blue-ear disease that broke out in some areas of my country in 2006 is an acute and highly lethal disease caused by a mutant strain of the porcine reproductive and resp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/295A61P31/14A61P31/04A61P11/00A61K39/12A61K39/102
Inventor 田克恭张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com